USDA Agrees ECI® Demonstrates Reasonable Expectation of Efficacy for the Treatment of Bone Cancer in Dogs
First-in-class adoptive cell therapy achieves critical milestone in the licensure pathway
USDA Agrees ECI® Demonstrates Reasonable Expectation of Efficacy for the Treatment of Bone Cancer in Dogs
First-in-class adoptive cell therapy achieves critical milestone in the licensure pathway
ELIAS Cancer Immunotherapy (ECI®) Treatment for Dogs
One in four dogs will develop cancer in their lifetime. Cancer is the leading cause of death in dogs over the age of two. It’s often discovered in late stages of the disease when treatment is difficult. Families of these pets are urgently looking for new and better options that not only prolong their companion’s life, but also improve quality of life. ELIAS Animal Health is elevating the hope of veterinarians and pet owners alike by changing the way cancer is fundamentally treated.
ELIAS Animal Health, in collaboration with local veterinarians and veterinary hospitals, is helping these dogs and their families address this reality.
We Are Changing the Way Cancer is Fundamentally Treated
Cancer Immunotherapy. Personalized
Our approach is profoundly simple: Every canine patient is unique. Every cancer is unique. To ultimately win against this devastating killer, cancer therapy itself must also be unique. ELIAS Cancer Immunotherapy (ECI®), our Autologous Prescription Product, harnesses the power of the dog’s own immune system to eliminate the cancer.
Killer T cells. Activated.
The complexity of cancer itself makes the development and delivery of effective treatments a steep challenge. Research has shown that ex vivo activated T cells have the capability to effectively kill cancer cells, including cancer stem cells. ELIAS cancer immunotherapy utilizes adoptive cell therapy to deliver an army of activated T cells.
Two Methods. Combined.
ELIAS Animal Health has developed a unique treatment protocol that vaccinates the dog with its own cancer cells to produce an immune response. Personalized T cells are then safely obtained from the patient through apheresis and activated to produce a large population of killer T cells that are reinfused into the patient to kill the cancer.
Benefits. Expanded.
ELIAS’ cancer immunotherapy is a platform technology that has demonstrated effectiveness in multiple rodent and human cancers, while avoiding or minimizing the need for chemotherapy or radiation treatment. ELIAS is taking cancer treatment to new heights.
What Veterinarians Are Saying About ECI®
Carolyn Henry, DVM, MS, DACVIM (Oncology)
Dean, College of Veterinary Medicine,
University of Missouri
Jeffrey Bryan, DVM, MS, PhD, DACVIM (Oncology)
Associate Professor & Director of the Comparative Oncology and Epigenetics Laboratory, College of Veterinary Medicine, University of Missouri